ライフサイエンスコーパス: ofloxacin

1 oglycoside (amikacin) and a fluoroquinolone (ofloxacin).

2 ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

3 ipenem and with Klebsiella pneumoniae versus ofloxacin.

4 tibility to ciprofloxacin, sparfloxacin, and ofloxacin.

5 d a rate that is comprehensibly half that of ofloxacin.

6 at potentiate the fluoroquinolone antibiotic ofloxacin.

7 ncrease persisters to ampicillin compared to ofloxacin.

8 m (S), 16 to 24 mm (I), and </=15 mm (R) for ofloxacin.

9 norfloxacin, and 1.17 (95% CI, .59-2.31) for ofloxacin.

10 g amoxicillin, ampicillin, lomefloxacin, and ofloxacin.

11 in 1%, gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%) and used only their assigned antibiotic

12 mug/ml), moxifloxacin (0.06 to 0.5 mug/ml), ofloxacin (0.25 to 2 mug/ml), amikacin (0.25 to 2 mug/ml

13 Corneas were treated with gentamicin and ofloxacin (0.3%) or gentamicin alone, some also treated

14 oxicillin was predominantly prescribed, only ofloxacin (1 ng.L(-1)) and sulfamethoxazole (4 ng.L(-1))

15 ard ratios were 1.49 (95% CI, 1.05-2.09) for ofloxacin, 1.94 (95% CI, 1.32-2.85) for ciprofloxacin pl

16 ifampicin]; rrs 1400 [kanamycin]; gyrA A90V [ofloxacin]; 1995 [95% HPD: 1988-1999]) prior to the outb

17 ard ratios were 2.53 (95% CI, 1.27-5.05) for ofloxacin, 2.24 (95% CI, 1.03-4.85) for ciprofloxacin pl

18 Resistance rates were the following: 35.1% ofloxacin, 34.2% levofloxacin, 33.3% moxifloxacin, 1.5%

19 otaxime, a cell wall synthesis inhibitor, to ofloxacin, a fluoroquinolone inhibitor of DNA gyrase, an

20 ion against ciprofloxacin, levofloxacin, and ofloxacin and by disk diffusion using EUCAST or CLSI met

21 7.45% and 9.58% for amikacin, moxifloxacin, ofloxacin and capreomycin, respectively, as well increas

22 with the clinical isolates was achieved with ofloxacin and chloramphenicol (100%), and the lowest lev

23 oup of antibiotics (moxifloxacin followed by ofloxacin and ciprofloxacin).

24 s resulted in 92% category agreement between ofloxacin and ciprofloxacin.

25 ins did not protect cells from cefotaxime or ofloxacin and had an impaired ability to protect from mi

26 nt tuberculosis strains and quantified their ofloxacin and moxifloxacin MIC by testing growth at six

27 There was 100% concordance between ofloxacin and moxifloxacin susceptibilities.

28 conferred different levels of resistance to ofloxacin and moxifloxacin.

29 n at the lowest concentration (0.003 mg/ml), ofloxacin and norfloxacin inhibited keratocyte prolifera

30 confer resistance to isoniazid, rifampicin, ofloxacin and streptomycin.

31 ate), the fluoroquinolones ciprofloxacin and ofloxacin and vemurafenib.

32 Among regulated genes, 31 eQTLs (without ofloxacin) and 35 eQTLs (with ofloxacin) had significant

33 these, Rv1410c, Rv2459, and Rv3756c (without ofloxacin) and Rv0191 and Rv3756c (with ofloxacin) have

34 uoroquinolones (ciprofloxacin, levofloxacin, ofloxacin), and beta-lactams to treat UTI.

35 Furthermore, ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin exhibited concentration-depe

36 at confer resistance to isoniazid, rifampin, ofloxacin, and moxifloxacin occur the most frequently.

37 d no very major errors, one major error with ofloxacin, and numerous minor errors with the quinolones

38 Ciprofloxacin, ofloxacin, and pefloxacin disks detected all isolates re

39 loci for 16 in vitro-derived recombinants of ofloxacin- and rifampin-resistant L(1) and D strains, re

40 m, cefpodoxime, ciprofloxacin, levofloxacin, ofloxacin-and decreased for one drug: cefdinir.

41 generation quinolones, (aOR: 2.7 [1.7-4.3]), ofloxacin (aOR: 2.3 [1.3-3.8]), ethionamide or prothiona

42 ted odds ratio [aOR]: 2.5 [95% CI 1.1-6.0]), ofloxacin (aOR: 2.5 [1.6-3.9]), ethionamide or prothiona

43 Dehydro- and desmethyl-ofloxacin are further oxidized through several identifie

44 Systemic ofloxacin as adjunct to open flap surgery is able to sup

45 resistance to doxycycline, azithromycin, and ofloxacin at concentrations >4.0 microg/mL.

46 eakpoints for Salmonella to levofloxacin and ofloxacin, but breakpoints for assigning disk diffusion

47 levofloxacin and 4 of 4 laboratories testing ofloxacin by an MIC method correctly reported resistant

48 r susceptibility to rifampin, isoniazid, and ofloxacin by using the conventional submerged-disk propo

49 which results in a moderate increase in the ofloxacin, carbenicillin, and tobramycin MICs.

50 , patients were treated with single doses of ofloxacin, cefixime, or ceftriaxone.

51 gh sensitivity, with limits of detection for ofloxacin, chloramphenicol, and streptomycin of 0.3, 0.1

52 Included ear drops were ofloxacin, ciprofloxacin plus hydrocortisone, ciprofloxa

53 Included ear drops were quinolones (ofloxacin, ciprofloxacin plus hydrocortisone, or ciprofl

54 ic data obtained with selectively deuterated ofloxacin compounds revealed for desaturation and N-deme

55 o-electrons above the ferric state producing ofloxacin desaturation via sequential hydrogen atom abst

56 Neither the levofloxacin nor the ofloxacin disk yielded good separation of isolates with

57 on preventive therapy as per local guidance: ofloxacin, ethambutol, and high-dose isoniazid for 6 mon

58 katG (isoniazid), pncA (pyrazinamide), gyrA (ofloxacin/fluoroquinolone), and rrs (aminoglycosides)-we

59 hen randomized at day 3-4 to either continue ofloxacin for 14 days total treatment, or for 7 days fol

60 detection of Aa were treated with 2x200 mg/d ofloxacin for 5 days as adjunct to open flap surgery (te

61 A treatment with ofloxacin for 7 days was inferior to 14 days for febrile

62 hway by which Escherichia coli persisters to ofloxacin form in response to a carbon source transition

63 Even though the high level of resistance to ofloxacin found in Pakistan is worrisome because it migh

64 eQTLs (without ofloxacin) and 35 eQTLs (with ofloxacin) had significant allele frequency differences

65 hout ofloxacin) and Rv0191 and Rv3756c (with ofloxacin) have previously been associated with antitube

66 ODELAM identified ofloxacin heteroresistance and the presence of drug resi

67 he cases of levofloxacin, ciprofloxacin, and ofloxacin, inhibition of HERG occurs at concentrations m

68 luoroquinolone antibiotics ciprofloxacin and ofloxacin interact with UVA radiation to generate reacti

69 Ofloxacin is a fluoroquinolone antibiotic that kills non

70 herichia coli, and found that persistence to ofloxacin is inversely correlated with the capacity of n

71 oxacin, the active l-isomer of the quinolone ofloxacin, is now widely accepted for treatment of multi

72 haloperidol, erythromycin, procainamide, and ofloxacin known to activate T2Rs.

73 populations were eradicated at low levels of ofloxacin, leaving a fraction of essentially invulnerabl

74 d, 98.7% for rifampin, 97.6% for quinolones (ofloxacin, levofloxacin, or moxifloxacin), 99.2% for ami

75 Evidence is mounting that ciprofloxacin and ofloxacin may be safely used to treat serious infections

76 regimens consisted mainly of ethambutol and ofloxacin; mean length of therapy 9 months.

77 inst the ciprofloxacin MICs and that the new ofloxacin MIC breakpoints resulted in 92% category agree

78 Of these 27, 7 had >2-fold reduction in ofloxacin MIC with verapamil; 6 had 2-fold reduction, an

79 We determined ofloxacin minimum inhibitory concentration (MIC) for ofl

80 thambutol, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide, para-aminosalicyli

81 eptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide, para-aminosalicyli

82 gentamicin (n = 4360), imipenem (n = 2235), ofloxacin (n = 3117), and sulfamethoxazole-trimethoprim

83 42), Gentamicin (n=4360), Imipenem (n=2235), Ofloxacin (n=3117) and Sulfamethoxazole-Trimethoprim (n=

84 For ofloxacin, no very major errors were observed, and major

85 us concentrations of gentamicin, tobramycin, ofloxacin, norfloxacin, and ciprofloxacin.

86 istics of sodium dodecyl sulfate (NaDS) with ofloxacin (OFC) drug different pH and in the occurrence

87 based on triple-emission sensing system for ofloxacin (OFL) detection in complex food matrices.

88 Antibiotics, such as ofloxacin (OFX) and ciprofloxacin (CFX), are often detec

89 The surface complexation behavior of ofloxacin (OFX), a zwitterionic fluoroquinolone antibiot

90 d (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and ca

91 norfloxacin (NRFX, IC(50), 0.78 mug L(-1)), ofloxacin (OFX, IC(50), 1.84 mug L(-1)), flumequine (Flu

92 The quinolone-specific aptamers bound to ofloxacin, one of the most frequently prescribed fluoroq

93 Participants were treated with ofloxacin or a third-generation cephalosporin at day 1,

94 Preoperative topical application of ofloxacin or ciprofloxacin results in a satisfactory min

95 , participating women initiated therapy with ofloxacin or levofloxacin.

96 roquinolone (ciprofloxacin, levofloxacin, or ofloxacin), or oral beta-lactam (amoxicillin-clavulanate

97 comparator drugs: cefixime, chloramphenicol, ofloxacin, or ceftriaxone.

98 n (p = 0.001), gatifloxacin (p = 0.003), and ofloxacin (p = 0.002) compared to exoU(-) isolates.

99 equired for formation of both ampicillin and ofloxacin persisters, and we demonstrated that higher sy

100 nucleoid-associated proteins were unique for ofloxacin persisters.

101 gain (median of 1 kg), and the finding that ofloxacin plus ursodeoxycholic acid was not superior to

102 Ofloxacin produces two peaks in the ion mobility distrib

103 om 2002 to 2009 were screened for phenotypic ofloxacin resistance (>2 mug/ml).

104 ce method for detection of ciprofloxacin and ofloxacin resistance in 195 clinical isolates of the fam

105 demonstrate ODELAM's utility by identifying ofloxacin resistance in cultured clinical isolates of Mt

106 High levels of ofloxacin resistance were detected in Pakistan.

107 As expected, gyrA (confers ofloxacin resistance) and rpoB (confers rifampin resista

108 r detecting DNA gyrase mutations that confer ofloxacin resistance, and was therefore the optimal thre

109 t cells were simultaneously infected with an ofloxacin-resistant (Ofx(r)) mutant of a serovar L1 stra

110 n minimum inhibitory concentration (MIC) for ofloxacin-resistant and -susceptible Mtb isolates withou

111 Phenotypically ofloxacin-resistant and lineage-matched ofloxacin-suscep

112 Of 25 ofloxacin-resistant isolates, 11 (44%) did not have prev

113 Of 42 ofloxacin-resistant Mtb isolates, 27 had adequate WGS co

114 Of 42 ofloxacin-resistant Mtb isolates, area under the ROC cur

115 fected in the absence of antibiotics with an ofloxacin-resistant mutant and a second mutant that was

116 The spatial distribution of percentage ofloxacin-resistant TB hotspots was similar to XDR-TB ho

117 rcentage and count of amikacin-resistant and ofloxacin-resistant TB.

118 Cape Town, as well as amikacin-resistant and ofloxacin-resistant TB.

119 tol, rifampicin, pyrazinamide, isoniazid and ofloxacin respectively).

120 d 10.14% for pyrazinamide, ciprofloxacin and ofloxacin, respectively (P < 0.01).

121 on of resistance to rifampin, isoniazid, and ofloxacin, respectively.

122 m abstraction to form dehydro- and desmethyl-ofloxacin, respectively; desaturation is a novel express

123 We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and streptomycin resistance in My

124 The temporal toxicity profile of ofloxacin's degradation intermediates based on in silico

125 2)O(2) activated catalyst (AC) first attacks ofloxacin's piperazine unit in two enzyme-mimicking para

126 utical contaminants (naproxen, danofloxacin, ofloxacin, sarafloxacin, and enoxacin) in environmental

127 eroxide C-H bond activations, cannot oxidize ofloxacin sp(3) C-H bonds.

128 river, only persistent antibiotic compounds (ofloxacin, sulfamethoxazole) were found, but they did no

129 For each resistant isolate, two ofloxacin-susceptible isolates were selected: one with a

130 ally ofloxacin-resistant and lineage-matched ofloxacin-susceptible Mtb isolates underwent whole-genom

131 May 2010 through April 2011 if exposed to an ofloxacin-susceptible, MDR tuberculosis source case.

132 ed antibiotics (sulfamethazine, norfloxacin, ofloxacin, tetracycline, and erythromycin) have been det

133 late displayed resistance to the antibiotics ofloxacin, tetracycline, ciprofloxacin, select fungi, as

134 ounds (e.g., propylparaben, norfloxacin, and ofloxacin), thanks to its combined effects of improved s

135 For ofloxacin, the 2/H(2)O(2) activated catalyst (AC) first

136 e MIC zone scattergrams for levofloxacin and ofloxacin, the following disk diffusion breakpoints gene

137 f the present study was to evaluate systemic ofloxacin therapy as adjunct to flap surgery.

138 and 12 months following adjunctive systemic ofloxacin therapy, Aa was suppressed below detectable le

139 s on cerulenin, chlorpromazine, ethionamide, ofloxacin, thiolactomycin and triclosan.

140 ions of resistance ranged from 1.0-16.6% for ofloxacin, to 0.5-12.4% for levofloxacin, and 0.9-14.6%

141 nitor Escherichia coli populations following ofloxacin treatment, we find that persisters filament ex

142 A photoactivation of 6-TG, ciprofloxacin and ofloxacin was associated with the generation of singlet

143 splaying an IC50 value of 18 microM, whereas ofloxacin was the least potent compound, with an IC50 va

144 he MICs for ciprofloxacin, levofloxacin, and ofloxacin were >32 mug/ml for all isolates.

145 Azithromycin and ofloxacin were detected in bioaerosols collected near ae

146 M. tuberculosis isolates to moxifloxacin and ofloxacin were determined by the agar proportion indirec

147 dixic acid, ciprofloxacin, levofloxacin, and ofloxacin were determined for 100 clinical isolates of n

148 showed increased tolerance to ampicillin and ofloxacin, while a strain with glpD deleted had a decrea

149 Combining topical gatifloxacin or ofloxacin with intracameral agent was not more effective

150 rmed the cross-reactivity of levofloxacin or ofloxacin with these opiate screening assays.